Athersys to cut up to 70% of its workers in effort to survive
June 02, 2022 at 18:35 PM EDT
Athersys has been developing its MultiStem adult stem cell therapy since 1994 but has a hard time commercializing it.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|